Dr. Kevin P. C. Minbiole
Organic and Natural Products Chemistry
Assistant Professor of Chemistry
office: 300A Mendel Hall
We have two 2013 papers: in
International Journal of Dermatology (in press).
Check out a
press release regarding our NSF grant.
See a picture from
a picture from our 2012
Robby for defending his MS thesis. Robby heads to the Vanderbilt
Chemistry PhD program this summer!
Welcome to our incoming group members:
Tom, Anthony, and Celina!
Research Interests: Nature provides us with a tremendous variety
of small molecules that possess fascinating structure and potent
medicinal properties. Their biological origin is as diverse as their
chemical composition (see below). Research in this group aims to
identify and synthesize naturally occurring heterocycles with significant biological
function (antifungal, anticancer, antimalarial, neuromodulatory). We also
working to prepare novel antibacterial/antiseptic compounds to combat
antibiotic-resistant bacterial infections.
Natural Product Isolation Project: Globally, amphibians
face one of the largest extinction rates in the animal kingdom. Although
habitat destruction is a major cause of amphibian extinctions, infection
from the fungal pathogen, Batrachochytrium dendrobatidis, is a
large contributor. Our group is working in collaboration with
Reid Harris at James Madison University and
Dr. Lisa Belden
at Virginia Tech to examine bacterially-produced natural
products endemic to the skins of frogs and salamanders that may confer
protection against this chytrid fungus. This was highlighted in a special on the Smithsonian Channel; see the
preview. We have also begun a collaboration with
Dr. Louise Rollins-Smith at Vanderbilt University, to further
investigate Bd. We also have a collaboration with
Dr. Gail Hearn's Lab
at Drexel University, to improve our
metabolite sampling protocol using swabs.
Panamanian Golden Frog, photo by B. Gratwicke
Three compounds we've isolated from bacteria on salamander skin.
Medicinal Chemistry Project: Bacteria are developing
resistance at a rate faster than new antibiotics are coming to
market. Using a novel polycephalic (multi-headed) platform, we
are developing novel antiseptics to more efficiently disrupt cell
membranes and lyse bacteria.
our recent paper in this area!